¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"growth recovery line"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • arcuate line
    Ȱ²Ã¼±
  • axillary line
    °Üµå¶û¼±, ¾×¿Í¼±
  • blood line
    Ç÷Á·°è, Ç÷Åë
  • blue line
    û»ö¼±
  • cleavage line
    ºÐÇÒ¼±
  • continuous cell line
    ¹«ÇÑÁõ½Ä¼¼Æ÷ÁÖ, ¿¬¼Ó°è´ë¼¼Æ÷ÁÖ
  • cell line
    ¼¼Æ÷ÁÖ, ¼¼Æ÷°è
  • cement line
    ½Ã¸àÆ®¼±, °áÇÕ¼±
  • dynamic skin line
    µ¿ÀûÇǺμ±
  • developmental line
    ¹ß´Þ¼±, ¹ßÀ°À¶ÇÕ¼±
  • diploid cell line
    µÎ¹è¼öü¼¼Æ÷°è, À̹èü¼¼Æ÷°è
  • embryonic line
    ¹è¾Æ¼±
  • epiphyseal line
    »À³¡¼±, °ñ´Ü¼±
  • established cell line
    È®¸³¼¼Æ÷ÁÖ
  • fixation line
    Áֽü±
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • transforming growth factor
    Àüȯ¼ºÀåÀÎÀÚ
  • vascular endothelial growth factor
    Ç÷°ü³»ÇǼºÀåÀÎÀÚ
  • growth
    ¼ºÀå, Áõ½Ä
  • intrauterine growth restriction
    Àڱ󻼺ÀåÁö¿¬
  • growth spurt
    ¼ºÀå±ÞÁõ
  • peak growth velocity
    Ãִ뼺Àå¼Óµµ
  • growth zone
    ¼ºÀ屸¿ª
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • anchorage independent growth
    ºñºÎÂøÁõ½Ä, ºñºÎÂø¹ßÀ°
  • anocutaneous line
    Ç×¹®ÇǺμ±
  • apical growth
    ³¡¼ºÀå
  • appositional growth
    µ¡ºÙÀ̼ºÀå
  • arcuate line
    Ȱ²Ã¼±
  • asynchronous growth
    ºñµ¿Á¶Áõ½Ä
  • growth abnormality
    ¼ºÀåÀÌ»ó
  • growth acceleration
    ¼ºÀå°¡¼Ó
  • mesiolingual line angle
    ¾ÈÂÊÇôÂʼ±°¢
  • mesioocclusal line angle
    ¾ÈÂʸ¹°¸²¸é¼±°¢, ¾ÈÂʱ³Çո鼱°¢
  • plane-line articulator
    Æò¸é¼±±³ÇÕ±â
  • bacterial growth rate
    ¼¼±ÕÁõ½Ä·ü
  • base line
    ¹ÙÅÁ¼±, ±âÁؼ±
  • base line shift
    ±âÁؼ±À̵¿
  • blood line
    Ç÷Á·°è
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Campers line
    įÆÛ¼±.
  • Frankfurt line
    À̰³¾È¿ÍÇϼöÆò¼±, ¿ÜÀ̵µ¼öÆò¼±
  • H-9 cell line
    H-9 ¼¼Æ÷°è
  • Haabs line
    ÇϺ꼱
  • Hudson-Staehli line
    Çãµå½¼-½ºÅŸ®¼±
  • Hudsons pigmented line
    Çãµå½¼»ö¼Ò¼±
  • KCL =keratoconus line
    ¿ø»Ô°¢¸·¼±.
  • Kerley s A line
    Äø® A¼±.
  • Kerley s B line
    Äø® B¼±.
  • Kerley s C line
    Äø® C¼±.
  • Kerleys A line
    Äø® A¼±
  • Kerleys B line
    Äø® B¼±
  • Kerleys C line
    Äø® C¼±
  • Kerleys D line
    Äø® D¼±
  • Langer line
    ¶û°Å¼±
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • postanesthetic recovery unit =PARU
    ȸº¹½Ç, ¸¶ÃëÈÄȸº¹À¯´Ö.
  • recovery
    ȸº¹
  • recovery quotient
    ȸº¹Áö¼ö(üáÜÖò¦â¦).
  • recovery room
    ȸº¹½Ç(üáÜÖãø).
  • recovery time
    ȸº¹ ±â°£ (üáÜÖ Ñ¢Êà)
  • recovery time
    ȸº¹ ±â°£, ȸº¹ ½Ã°£
  • restitutio ad integrum =complete recovery
    ÀüÄè(îïöá).
  • saturation recovery
    Æ÷È­ ȸº¹
  • sinus node recovery time
    µ¿°áÀýȸº¹½Ã°£.
  • spontaneous recovery, definition
    ÀÚ¿¬(Àû) ȸº¹(üÞÜÖ)
  • sulfur recovery
    À¯È²È¸¼ö(ËôÌ·Ì·Ëà).
  • abnormal growth
    ºñÁ¤»ó¼ºÀå
  • anchorage dependent growth
    ºÎÂøÁõ½Ä, ºÎÂø¹ßÀ°
  • anchorage independent growth
    ºñºÎÂøÁõ½Ä, ºñºÎÂø¹ßÀ°
  • anomalous growth
    ÀÌ»ó¼ºÀå.
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Pectineal line
    µÎµ¢»Àºø
    [¿¾ ¿ë¾î] Ä¡°ñ±Ù¼±
  • Posterior axillary line
    µÚ°Üµå¶û¼±
    [¿¾ ¿ë¾î] Èľ׿ͼ±
  • Posterior gluteal line
    µÚº¼±â±Ù¼±
    [¿¾ ¿ë¾î] Èĵбټ±
  • Posterior median line
    µÚÁ¤Áß¼±
    [¿¾ ¿ë¾î] ÈÄÁ¤Áß¼±
  • Trapezoid line
    ¸¶¸§Àδ뼱
    [¿¾ ¿ë¾î] ´ÉÇüÀδ뼱
  • Highest nuchal line
    ¸ÇÀ§¸ñ´ú¹Ì¼±
    [¿¾ ¿ë¾î] ÃÖ»óÇ×(¸ñ´ú¹Ì)¼±
  • Semilunar line
    ¹Ý´Þ¼±
    [¿¾ ¿ë¾î] ¹Ý¿ù¼±
  • Terminal line
    ºÐ°è¼±
    [¿¾ ¿ë¾î] ºÐ°è¼±
  • Midclavicular line
    ºøÀåÁß°£¼±
    [¿¾ ¿ë¾î] À¯µÎ¼±
  • Epiphyseal line
    »À³¡¼±
    [¿¾ ¿ë¾î] °ñ´Ü¼±
  • Incremental line of dentin
    »ó¾ÆÁú¼ºÀå¼±
    [¿¾ ¿ë¾î] »ó¾ÆÁú¼ºÀå¼±
  • Incremental line of cementum
    ½Ã¸àÆ®Áú¼ºÀå¼±
    [¿¾ ¿ë¾î] ½Ã¸àÆ®Áú¼ºÀå¼±
  • Inferior temporal line
    ¾Æ·¡°üÀÚ¼±
    [¿¾ ¿ë¾î] ÇÏÃøµÎ¼±
  • Inferior nuchal line
    ¾Æ·¡¸ñ´ú¹Ì¼±
    [¿¾ ¿ë¾î] ÇÏÇ×(¸ñ´ú¹Ì)¼±
  • Inferior gluteal line
    ¾Æ·¡º¼±â±Ù¼±
    [¿¾ ¿ë¾î] Çϵбټ±
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • line spectrum
    ¼±(àÊ)½ºÆåÆ®·Ò
  • line splitting
    ¼±ºÐÇÒ(àÊÝÂùÜ)
  • pure line
    ¼ø¼ö °èÅë(ͧ÷Ö)
  • regression line
    ȸ±Í¼±(üÞÏýàÊ)
  • T cell line
    T ¼¼Æ÷ÁÖ(á¬øàñ»)
  • Z line
    Z ¼±(àÊ)
  • anchorage independent growth
    °íÁ¤ºñÀÇÁ¸¼º¼ºÀå(ͳïÒÞªëîðíàõà÷íþ)
  • asynchronous growth
    ºñµ¿½Ã¼º ¼ºÀå (ÞªÔÒãÁàõà÷íþ)
  • balanced growth
    ±ÕÇü¼ºÀå(гû¬à÷íþ)
  • chain-growth polymer
    »ç½½½ÅÀå(ãßíþ)ÁßÇÕü(ñìùêô÷)
  • comb growth test
    °è°ü ¼ºÀå½ÃÇè(ͮήà÷íþãËúÐ)
  • confluent growth
    Àü¸é¼ºÀå(îïØüà÷íþ)
  • density-dependent growth
    "¹ÐµµÀÇÁ¸ ¼ºÀå(ÚËÓøëîðíà÷íþ), (ÔÒ) contact inhibition"
  • epidermal growth factor
    Ç¥ÇǼºÀåÀÎÀÚ (øúù«à÷íþì×í­)
  • epithelial growth factor
    »óÇǼºÀåÀÎÀÚ (ß¾ù«à÷íþì×í­)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • recovery room
    ȸº¹½Ç
  • recovery time
    ȸº¹±â°£, ȸº¹ ½Ã°£
  • saturation recovery
    Æ÷ȭȸº¹
  • short tau inversion recovery [=STIR]
    ´Ü½Ã°£¹ÝÀüȸº¹
  • STIR [=short tau inversion recovery]
    ´Ü½Ã°£¹ÝÀüȸº¹
  • T1 recovery
    T1ȸº¹
  • anterior axillary line
    Àü¾×¿Í¼±
  • base line
    ±âÁؼ±
  • base line shift
    ±âÁؼ±º¯À§
  • black line , linea nigra
    Èæ¼±
  • dentate line
    Ä¡¾Æ¼±, Ä¡»ó¼±
  • digastic line
    À̺¹¼±
  • gluteal line
    µÐºÎ±Ù¼±, µÐ±Ù¼±
  • Kerley's A line
    Äø® A¼±
  • Kerley's B line
    Äø® B¼±
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
NG nasogastric; neoplastic growth; new growth; nitroglycerin; nodose ganglion; no growth; not given
TGF T-cell growth factor; transforming growth factor; tuboglomerular feedback; tumor growth factor
CCL carcinoma cell line; certified cell line; Charcot-Leyden crystal; continuing care level; critical ca...
LCL Levinthal-Coles-Lillie [body]; lower confidence limit; lower control limit; lymphoblastoid cell line...
MCL maximum containment laboratory; medial collateral ligament; midclavicular line; midcostal line; mini...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
FRAP Fluorescence Recovery After Photobleaching
FPR Fluorescence photobleaching recovery
IR Inversion Recovery
STIR Inversion Time Inversion Recovery
LHR Liquid holding recovery
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • centrifugal growth
    ¿ø½É¼º ¼ºÀå
  • controlling factors in facial growth
    ¾È¸é ¼ºÀåÀÇ Á¶Àý ¿äÀÎ
  • deep invasive growth
    ½ÉºÎ ħÀÔ¼º ¼ºÀå
  • eccentric growth
    Æí½É ¼ºÀå
  • endochondral bone growth
    ¿¬°ñ³» °ñ ¼ºÀå
  • exclusively centrifugal growth
    ¹èŸÀû ¿ø½É ¼ºÀå
  • exponential growth
    Áö¼ö Áõ½Ä
  • exponential phase of growth
    ´ë¼ö Áõ½Ä±â, °¡¼Ó ¼ºÀå±â
  • horizontal growth
    ¼öÆò ¼ºÀå
  • human growth hormone
    ¼ºÀå È£¸£¸ó
    ¼ºÀåÀ» ÃËÁøÇÏ´Â ¹°ÁúÀ» ÃÑĪÇϸç, ƯÈ÷ ³úÇϼöü Àü¿±¿¡¼­ ºÐºñµÇ´Â È£¸£¸óÀ» ¸»ÇÑ´Ù.
  • neural growth
    ½Å°æ°èÇü ¼ºÀå
  • no growth
    ¹«¼ºÀå
  • nonbleeding growth
    ºñÃâÇ÷¼º ¼ºÀå
  • one step growth
    ÀÏ´Ü Áõ½Ä
  • papillomatous growth
    À¯µÎ¼º ¼ºÀå
    À¯µÎÁ¾°ú °°ÀÌ ´Ù¹ßÀûÀ¸·Î ÀϾ´Â ¼ºÀå.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
fluorescence recovery after photobleaching Many fluorochromes are bleached by exposure to exciting light. If, for example: the cell surface is labelled with a fluorescent probe and an area bleached by laser illumination, then the bleached patch that starts off as a dark area will gradually recover fluorescence. The recovery is due to the re population of the area by unbleached molecules and diffusion of bleached molecules to other areas. The rate and extent of recovery are a measure of the fluidity of the membrane and the proportion of labelled molecules that are free to exchange with adjacent areas. The technique is usually applied to cell surface fluidity or viscosity measurements, but is also applicable to other structures.
(18 Nov 1997)
accretionary growth Growth by an increase of intercellular material.
(05 Mar 2000)
appositional growth Growth accomplished by the addition of new layers on those previously formed; e.g., the addition of lamellae in the formation of bone; it is the characteristic method of growth when rigid materials are involved.
(05 Mar 2000)
auxetic growth Growth by increase in the size of component cells.
Synonym: intussusceptive growth.
(05 Mar 2000)
bacterial growth Growth of a bacterial culture either by increase in cell material or cell number.
(05 Mar 2000)
B-cell differentiation/growth factors Various substances, usually obtained from the supernatant of T-cell cultures, such as interleukin 4, 5, and 6. These substances are necessary for B-cell growth, maturation, and differentiation into plasma cells or B memory cells.
(05 Mar 2000)
biphasic growth curve <cell culture, microbiology> A particular type of growth curve seen in cultured microorganisms in which they have two exponential growth stages separated by a plateau phase. This double-hump curve is produced when the microbes are cultured using two carbon sources, one of which must be used up before the second can be used.
(19 Jan 1998)
bovine growth hormone <endocrinology> A hormone secreted by the bovine pituitary gland. It is used to increase milk production by improving the feed efficiency in dairy cattle.
(14 Nov 1997)
brain-derived growth factor <growth factor> Small basic protein purified from pig brain, a member of the family of neurotrophic factors that also includes Nerve Growth Factor and neurotrophin 3.
In contrast to nerve growth factor, brain-derived neurotrophic factor is predominanantly (though not exclusively) localised in the CNS. It supports the survival of primary sensory neurons originating from the neural crest and ectodermal placodes that are not responsive to NGF.
In the brain brain-derived neurotrophic factor has a trophic action on retinal, cholinergic, and dopaminergic neurons, and in the peripheral nervous system it acts on both motor and sensory neurons.
Acronym: BDGF
(12 Dec 1998)
capon-comb-growth test A test for androgenic activity, based upon the stimulation of comb growth in capons (castrated cockerels) or immature roosters.
Synonym: capon-comb-growth test, cock's comb test.
(05 Mar 2000)
radial growth phase The early pattern of growth of cutaneous malignant melanoma, in which tumour cells spread laterally in the epidermis.
(05 Mar 2000)
vascular endothelial growth factor A growth factor that is responsible for the growth of blood vessels.
(12 Dec 1998)
mammary derived growth inhibitor Fatty acid binding protein that inhibits proliferation of mammary carcinoma cells.
(18 Nov 1997)
receptors, epidermal growth factor-urogastrone Glycoproteins of about 170 kD that have protein kinase activity and span the plasma membranes of growing cells, including tumours. They are activated by the binding of epidermal growth factor-urogastrone which then initiates DNA and protein synthesis. They are not found on mitotically quiescent cells except in the stomach where they control the synthesis and release of digestive enzymes and gastric acid. Transforming growth factor alpha also binds to and activates these receptors.
(12 Dec 1998)
receptors, fibroblast growth factor Specific molecular sites or structures on cell membranes that react with fibroblast growth factors (both the basic and acidic forms), their analogs, or their antagonists to elicit or to inhibit the specific response of the cell to these factors. These receptors frequently possess tyrosine kinase activity.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • nerve growth factor
    (»ý¸®)½Å°æ ¼ºÀåÀÎÀÚ(Áö°¢(±³°¨)½Å°æ¼¼Æ÷ÀÇ ¼ºÀåÀ» ÀÚ±ØÇÏ´Â ´Ü¹éÁú)
  • positive growth
    Ç÷¯½º ¼ºÀå
  • air-line
    °ø·Î¿¡ ÀÇÇÑ
  • bottom line
    °á°ú, ¼øÀÌÀÍ
  • by-line
    À̸§ÀÌ ¾º¾îÀÖ´Â Çà
  • in line with
    -¿Í ÀÏÄ¡ÇÏ¿©
  • line
    ¼±,¿­,³ª¶õÀÌÇÏ´Ù
  • main line
    °£¼±
  • two-line
    ¹èÇüÀÇ
  • A line
    ¶óÀÎÀÇ;A¶óÀÎÀÇ(¿©¼ºº¹ÀÌ AÀÚó·³ À§°¡ Á¼°í ¹ØÀÌ ÆÛÁü)
  • DEW line
    µà¶óÀÎ(ºÏ±Ø±Ç ºÏºÎ¿¡ ÀÖ´Â ¹Ì±¹.ij³ª´Ù °øµ¿ÀÇ ¿ø°Å¸®Á¶±â °æº¸¸Á)
  • Distant Early Warning line
    =DEW LINE
  • Gray Line
    ¹Ì±¹ÀÇ ´ë±Ô¸ð °ü±¤¹ö½º ȸ»ç
  • International Date Line
    ±¹Á¦ ³¯Â¥ º¯°æ¼±(IDL)
  • Mason Dixon line
    MarylandÁÖ¿Í PennsylvaniaÁÖÀÇ °æ°è¼±(³ë¿¹ ½Ã´ëÀÇ ³²ºÏ °æ°è¼±,ÇöÀç´Â ¹æ¾ð ±¸ºÐ¼±ÀÇ Çϳª)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á